Onxeo

EU: ONXEO

€44.1m market cap

€0.8 last close

Onxeo is developing innovative oncology drugs based on DNA-targeting and epigenetics. The lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism and currently evaluated in a phase I trial (DRIIV-1) for systemic administration in solid tumors.

Investment summary

Onxeo’s lead asset AsiDNA, a first-in-class DNA break repair inhibitor, is now being tested in the Phase Ib/II part of the DRIIV-1 trial at the Institut Curie in Paris in patients with advanced solid tumours. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection, but is now being tested via systemic administration. Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. AsiDNA is part of the proprietary, novel platON platform, a major R&D expansion announced in October 2017, and is based on decoy oligonucleotides. The platON platform belongs to the so-called DNA damage response (DDR) technology, a domain to which recently marketed PARP inhibitors also belong. After receiving $7.5m from the sale of rights to royalties from Beleodaq and a €5.4m equity financing line, cash reach will extend into Q320 past the AsiDNA Phase I results.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (fd) (c)
P/E (x)
P/CF (x)
2017A 9.5 (17.4) (19.7) (23.58) N/A N/A
2018A 6.1 (3.0) (4.2) 5.09 15.8 N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Last updated on 23/05/2019
Industry outlook

The approval of the first PARP inhibitor (olaparib) has kick started the interest of both the scientific community and large pharma in the DNA Damage Response (DDR) field. Few biotechs are already positioned in this emerging field which may be the successor to immuno-oncology.

Last updated on 23/05/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (2.9) (10.4) (36.9)
Relative* 3.1 (11.1) (32.8)
52-week high/low €1.3/€0.8
*% relative to local index
Key management
Judith Greciet CEO
Nicolas Fellmann CFO
Valérie Leroy Director, Investor Relations & Corporate Com